BioReliance, the biologics and early-development services business under Sigma-Aldrich Corporation’s (SIAL) Specialty Fine Chemicals (SAFC) segment, commissioned a new world-class Clearance Services ...
BioReliance, a Rockville, Md.-based provider of biologic safety and specialized toxicology testing services, may finally have settled down after bouncing among three owners since 2004. During C&EN’s ...
Life science and technology company, Sigma-Aldrich Corporation (NasdaqGS:SIAL - News) announced that it has agreed to buy BioReliance Holdings Inc., from private equity firm Avista Capital Partners ...
WEST LAFAYETTE, Ind., July 12, 2021 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract ...
ROCKVILLE, Md., Sept. 12 BioReliance Corporation, aleading contract services organization for the biopharmaceutical andpharmaceutical industries, has contracted with Gentronix to offer ...
ROCKVILLE, Md.--(BUSINESS WIRE)--BioReliance Corporation announced today that David A. Dodd has been named President, Chief Executive Officer and Chairman of the Board of the Company, effective today.
BioReliance Corp. builds new offices Firm’s growth reflects vibrancy of state’s high-tech industries
BioReliance Corp. will begin construction on a new headquarters in Rockville today — tangible evidence of the company’s fast growth, a trend that has not gone unnoticed by Wall Street. The project ...
BioReliance signed an agreement to acquire the colonies required for the Big Blue® transgenic rodent (mice) mutation (TRM) assay and to obtain a license to its associated trademark from Agilent ...
ROCKVILLE, Md.--(BUSINESS WIRE)--BioReliance Corporation announced today that two of the company’s senior scientists will be presenting at Informa Life Sciences’ Viral Safety for Biologicals meeting ...
Mention the faltering economy to most chief executive officers and they frown. Mention it to Capers McDonald, head of BioReliance Corp., a contract service provider to the drug-making industry, and he ...
Invitrogen's deal to sell its pharmaceutical services division, BioReliance, came at a hefty discount. Less than three years after paying $500 million for the unit, the company announced yesterday ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results